Given the limited scope of biomarker assessments available at the time of analysis, this study provides limited insight into potential pathogenic mechanisms that may or may not diverge in LRRK2 parkinsonism CSFasynSAA− versus SAA+ cases. The gene discussed is LRRK2; the disease is Parkinsonism.